Selected Publications

Mills IG, Gaughan L, Robson C, Ross T, McCracken S, Kelly J and Neal DE. Huntingtin Interacting Protein 1 (HIP1) modulates the transcriptional activity of nuclear hormone receptors. J Cell Biol 2005; 170: 191-200. PubMed

Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ and Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117: 3539-3545. PubMed

Logan IR, Sapountzi V, Gaughan L, Neal DE and Robson CN. Control of human PIRH2 protein stability: involvement of the TIP60 and the proteasome. J Biol Chem 2004; 279: 11696-11704. PubMed

Frankel S, Davey Smith G, Donovan J and Neal D. Screening for prostate cancer. Lancet 2003; 361: 1122-1128. PubMed

Primary Research Publications

2008

Aitchison AA, Veerakumarasivam A, Vias M, Kumar R, Hamdy FC, Neal DE, Mills IG. Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. Prostate 2008; 68:661-74

Attard G, Clark J, Ambroisine L, Mills IG, Fisher G, Flohr P, Reid A, Edwards S, Kovacs G, Berney D, Foster C, Massie CE, Fletcher A, De Bono JS, Scardino P, Cuzick J, Cooper CS. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. British Journal of Cancer 2008; 99:314-320

Avery KN, Metcalfe C, Blazeby JM, Lane JA, Neal DE, Hamdy FC, Donovan JL. Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations? BJU International 2008; 102:1629-1633

Berney DM, Warren AY, Verma M, Kudahetti S, Robson JM, Williams MW, Neal DE, Powles T, Shamash J, Oliver RTD. Malignant germ cell tumours in the elderly: a histopathological review of 50 cases in men aged 60 years or over. Modern Pathology 2008; 21:54-59

Borlido J, Veltri G, Jackson AP, Mills IG. Clathrin is spindle-associated but not essential for mitosis. PLoS ONE 2008; 3:e3115.

Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, Hamdy F, Stephens P, Lane JA, Moore R, Donovan J. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncology 2008; 9:445-452

Cutress ML, Whitaker HC, Mills IG, Stewart M, Neal DE. Structural basis for the nuclear import of the human androgen receptor. Journal of Cell Science 2008; 121:957-68

Donovan JL, Lane JA, Peters TJ, Brindle L, Salter E, Gillatt D, Powell P, Bollina P, Neal DE, Hamdy FC; for the ProtecT Study Group. Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. Journal of Clinical Epidemiology 2008; Jul 9 [Epub ahead of print]

Down L, Metcalfe C, Avery K, Noble S, Lane JA, Neal DE, Hamdy FC, Donovan JL. Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified. Journal of Clinical Epidemiology 2008; Jul 9 [Epub ahead of print]

Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL; The UK Genetic Prostate Cancer Study Collaborators; British Association of Urological Surgeons' Section of Oncology; The UK ProtecT Study Collaborators; Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF. Multiple newly identified loci associated with prostate cancer susceptibility. Nature Genetics 2008; 40:316-21

Ghoussaini M, Song H, Koessler T, Al Olama AA, Kote-Jarai Z, Driver KE, Pooley KA, Ramus SJ, Kjaer SK, Hogdall E, Dicioccio RA, Whittemore AS, Gayther SA, Giles GG, Guy M, Edwards SM, Morrison J, Donovan JL, Hamdy FC, Dearnaley DP, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Brown PM, Hopper JL, Neal DE, Pharoah PD, Ponder BAJ, Eeles RA, Easton DF, Dunning AM; for the UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology and the UK ProtecT Study Collaborators. Multiple loci with different cancer specificities within the 8q24 gene desert. Journal of the National Cancer Institute 2008; 100:962-6

Guy M, Kote-Jarai Z, Giles GG, Al Olama AA, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL; The UK Genetic Prostate Cancer Study Collaborators13; British Association of Urological Surgeons' Section of Oncology and The UK ProtecT Study Collaborators13; Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jameson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF, Eeles RA. Identification of new genetic risk factors for prostate cancer. Asian Journal of Andrology 2008; Dec 1 [Epub ahead of print]

Haba Y, Williams MV, Neal DE, Ong JY, Ostrowski MJ, Ell PJ, Nargund V, Shamash J, Oliver RT. Stage migration and pilot studies of reduced chemotherapy supported by positron-emission tomography findings suggest new combined strategies for stage 2 nonseminoma germ cell tumour. BJU International 2008; 101:570-4

Hussain S, Gunnell D, Donovan J, McPhail S, Hamdy F, Neal DE, Albertsen P, Verne J, Stephens P, Trotter C, Martin RM. Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. BJU International 2008; 101:47-55

Massie CE, Mills IG. ChIPing away at gene regulation. EMBO Reports 2008; 9:337-43

Metcalfe C, Martin RM, Noble S, Lane JA, Hamdy FC, Neal DE, Donovan JL. Low risk research using routinely collected identifiable health information without informed consent: encounters with the Patient Information Advisory Group. Journal of Medical Ethics 2008; 34:37-40

Neal DE. Can we accurately identify men with low risk prostate cancer? Journal of Urology 2008; 180:1217-8

Olesen LE, Ford MGJ, Schmid E M, Vallis Y, Madan Babu M, Li P, Mills IG, McMahon HT, Praefcke GJK. Solitary and repetitive binding motifs for the AP2 complex ¿-appendage in amphiphysin and other accessory proteins. Journal of Biological Chemistry 2008; 283:5099-5109

Rosario DJ, Lane JA, Metcalfe C, Catto JW, Dedman D, Donovan JL, Neal DE, Hamdy FC, ProtecT Study Grp. Contribution of a single repeat PSA test to prostate cancer risk assessment: Experience from the ProtecT study. European Urology 2008; 53:777-784

Sahadevan K, Pickard RS, Neal DE, Hasan TS. Is continent diversion using the Mitrofanoff principle a viable long-term option for adults requiring bladder replacement? BJU International 2008; 102:236-40

Saeb-Parsy K, Veerakumarasivam A, Wallard MJ, Thorne N, Kawano Y, Murphy G, Neal DE, Mills IG, Kelly JD. MT1-MMP regulates urothelial cell invasion via transcriptional regulation of Dickkopf-3. British Journal of Cancer 2008; 99:663-9

Veerakumarasivam A, Scott HE, Chin S-F, Warren A, Wallard MJ, Grimmer D, Ichimura K, Caldas C, Collins VP, Neal DE, Kelly JD. High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53. Clinical Cancer Research 2008; 14:2527-34

Veerakumarasivam A, Goldstein LD, Saeb-Parsy K, Scott HE, Warren A, Thorne NP, Mills IG, Venkitaraman A, Neal DE, Kelly JD. AURKA overexpression accompanies dysregulation of DNA-damage response genes in invasive urothelial cell carcinoma. Cell Cycle 2008; 7:3525-33

Vias M, Massie CE, East P, Scott H, Warren A, Zhou Z, Nikitin AY, Neal DE, Mills IG. Pro-neural transcription factors as cancer markers. BMC Medical Genomics 2008; 1:17

Vias M, Ramos-Montoya A, Mills IG. Terminal and progenitor lineage-survival oncogenes as cancer markers. Trends in Molecular Medicine 2008; 14:486-94

Whitaker HC, Girling J, Warren AY, Leung H, Mills IG, Neal DE. Alterations in β-catenin expression and localization in prostate cancer. Prostate 2008; 68:1196-205

Whitaker HC, Wainer J, Vias M, Warren A, Sutherland H, Mills IG, Neal DE. LYRIC, a novel modulator of Wnt/β-catenin and androgen receptor signalling in prostate cancer. Oncogene 2008; In press.

2007

Aitchison A, Warren A, Neal D, Rabbitts P. RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. Prostate 2007; 67(6):638-644

Baumert H, Balaro A, Shah N, Mansouri D, Zafar N, Molinie V, Neal D. Reducing warm ischaemia time during laparoscopic partial nephrectomy: A prospective comparison of two renal closure techniques. Eur Urol 2007; 52(4):1164-1169

Dudderidge TJ, McCracken SR, Loddo M, Fanshawe TR, Kelly JD, Neal DE, Leung HY, Williams GH, Stoeber K. Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer. Br J Cancer 2007; 96(9):1384-1393

Johnson MI, Merrilees D, Robson WA, Lennon T, Masters J, Orr KE, Matthews JNS, Neal DE. Oral ciprofloxacin or trimethoprim reduces bacteriuria after flexible cystoscopy. BJU Int 2007; 100(4):826-829

Lane JA, Howson J, Donovan JL, Goepel JR, Dedman DJ, Down L, Turner EL, Neal DE, Hamdy FC. Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial. BMJ 2007; 335(7630):1139-1143

Lynch AG, Neal DE, Kelly JD, Burtt GJ, Thorne NP. Missing channels in two-colour microarray experiments: Combining single-channel and two-channel data. BMC Bioinformatics 2007; 8:Article 26

Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, Neal DE, Mills IG. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 2007; 8(9):871-878

Vias M, Burtt G, Culig Z, Veerakumarasivam A, Neal DE, Mills IG. A role for neurotensin in bicalutamide resistant prostate cancer cells. Prostate 2007; 67(2):190-202

Whitaker HC, Stanbury DPB, Brinham C, Girling J, Hanrahan S, Totty N, Neal DE. Labeling and identification of LNCaP cell surface proteins: A pilot study. Prostate 2007; 67(9):943-954

Wicker N, Carles A, Mills IG, Wolf M, Veerakumarasivam A, Edgren H, Boileau F, Wasylyk B, Schalken JA, Neal DE, Kallioniemi O, Poch O. A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. BMC Genomics 2007; 8:Article 84

2006

Aho T, Canal A, Neal DE. Fournier's gangrene. Nat Clin Pract Urol 2006; 3(1):54-57

Brindle LA, Oliver SE, Dedman D, Donovan JL, Neal DE, Hamdy FC, Lane JA, Peters TJ. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. BJU Int 2006; 98(4):777-782

Massie C, Mills IG. The developing role of receptors and adaptors. Nat Rev Cancer 2006; 6(5):403-409

Mills N, Metcalfe C, Ronsmans C, Davis M, Lane JA, Sterne JAC, Peters TJ, Hamdy FC, Neal DE, Donovan JL. A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study). Contemp Clin Trials 2006; 27(5):413-419

N'Dow J, Jordan N, Robson CN, Neal DE, Pearson JP. The bladder does not appear to have a dynamic secreted continuous mucous gel layer d prostate cancer in the UK. J Urol 2006; 173(6):2025-2031

Wallard MJ, Pennington CJ, Veerakumarasivam A, Burtt G, Mills IG, Warren A, Leung HY, Murphy G, Edwards DR, Neal DE, Kelly JD. Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer 2006; 94(4):569-577

2005

Gaughan L, Logan IR, Neal DE, Robson CN. Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res 2005; 33(1):13-26

Mills IG, Gaughan L, Robson C, Ross T, McCracken S, Kelly J, Neal DE. Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors. J Cell Biol 2005; 170(2):191-200

Nickel JC, Forrest JB, Tomera K, Hernandez-Graulau J, Moon TD, Schaeffer AJ, Krieger JN, Zeitlin SI, Evans RJ, Lama DJ, Neal DE, Sant GR. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: A multicenter, randomized, placebo controlled study. J Urol 2005; 173(4):1252-1255

2004

Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 2004; 10(14):4874-4884

Gunnell D, Oliver SE, Donovan JL, Peters TJ, Gillatt D, Persad R, Hamdy FC, Neal DE, Holly JMP. Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease? J Clin Endocrinol Metab 2004; 89(1):213-218

Halkidou K, Cook S, Leung HY, Neal DE, Robson CN. Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur Urol 2004; 45(3):382-389

Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDACI in hormone refractory prostate cancer. Prostate 2004; 59(2):177-189

Halkidou K, Logan IR, Cook S, Neal DE, Robson CN. Putative involvement of the histone acetyltransferase Tip60 in ribosomal gene transcription. Nucleic Acids Res 2004; 32(5):1654-1665

Logan IR, Sapountzi V, Gaughan L, Neal DE, Robson CN. Control of human PIRH2 protein stability - Involvement of TIP60 and the proteasome. J Biol Chem 2004; 279(12):11696-11704

N'Dow J, Pearson J, Neal D. Mucus production after transposition of intestinal segments into the urinary tract. World J Urol 2004; 22(3):178-185

Oliver RTD, Ong J, Shamash J, Ravi R, Nagund V, Harper P, Ostrowski MJ, Sizer B, LeVay J, Robinson A, Neal DE, Williams M. Long-term follow-up of anglian germ cell cancer group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology 2004; 63(3):556-561

Oliver SE, Barrass B, Gunnell DJ, Donovan JL, Peters TJ, Persad RA, Gillatt D, Neal DE, Hamdy FC, Holly JMP. Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13(1):163-165

Oliver SE, Gunnell D, Donovan J, Peters TJ, Persad R, Gillatt D, Pearce A, Neal DE, Hamdy FC, Holly J. Screen-detected prostate cancer and the insulin-like growth factor axis: Results of a population-based case-control study. Int J Cancer 2004; 108(6):887-892

Oliver SE, Holly J, Peters TJ, Donovan J, Persad R, Gillatt D, Pearce A, Hamdy FC, Neal DE, Gunnell D. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. Urology 2004; 64(2):317-322

Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117(16):3539-3545

2003

Donovan JL, Peters TJ, Noble S, Powell P, Gillatt D, Oliver SE, Lane JA, Neal DE, Hamdy FC, ProtecT Study Grp. Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study). J Clin Epidemiol 2003; 56(7):605-609

Drake MJ, Robson W, Mehta P, Schofield I, Neal DE, Leung HY. An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 2003; 88(6):822-827

Durkan GC, Nutt JE, Marsh C, Rajjayabun PH, Robinson MC, Neal DE, Lunec J, Mellon JK. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer. Clin Cancer Res 2003; 9(7):2576-2582

Frankel S, Smith GD, Donovan J, Neal D. Screening for prostate cancer. Lancet 2003; 361(9363):1122-1128

Gunnell D, Oliver SE, Peters TJ, Donovan JL, Persad R, Maynard M, Gillatt D, Pearce A, Hamdy FC, Neal DE, Holly JMP. Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. Br J Cancer 2003; 88(11):1682-1686

Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, Leung HY, Neal DE, Robson CN. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003; 22(16):2466-2477

Hamdy FC, Donovan JL, Lane JA, Neal DE. Ethics of clinical trials from bayesian perspective - Randomisation to clinical trials may solve dilemma of treatment choice in prostate cancer. BMJ 2003; 326(7404):1456-1456

Keegan SJ, Graham C, Neal DE, Blum-Oehler G, N'Dow J, Pearson JP, Gally DL. Characterization of Escherichia coli strains causing urinary tract infections in patients with transposed intestinal segments. J Urol 2003; 169(6):2382-2387

Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE, Leung HY. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 2003; 22(9):1381-1389

Mills N, Donovan JL, Smith M, Jacoby A, Neal DE, Hamdy FC. Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. Control Clin Trials 2003; 24(3):272-282

Oliver SE, Donovan JL, Peters TJ, Frankel S, Hamdy FC, Neal DE. Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion. BJU Int 2003; 91(4):331-336

Rigas AC, Ozanne DM, Neal DE, Robson CN. The scaffolding protein RACK1 interacts with androgen receptor and promotes cross-talk through a protein kinase C signaling pathway. J Biol Chem 2003; 278(46):46087-46093

Skolarikos A, Griffiths TRL, Powell PH, Thomas DJ, Neal DE, Kelly JD. Cytologic analysis of ureteral washings is informative in patients with grade 2 upper tract TCC considering endoscopic treatment. Urology 2003; 61(6):1146-1150

Other Publications

Kaul SA, Peabody JO, Shah N, Neal D, Menon M. Establishing a robotic prostatectomy programme: The impact of mentoring using a structured approach. BJU Int 2006; 97(6):1143-1144

Martin RM, Gunnell D, Hamdy F, Neal D, Lane A, Donovan J. Continuing controversy over monitoring men with localized prostate cancer: A systematic review of programs in the prostate specific antigen era. J Urol 2006; 176(2):439-449

Metcalfe C, Lane JA, Hamdy F, Neal D, Donovan JL, ProtecT Study Res Grp. A model of the natural history of screen-detected prostate cancer. Br J Cancer 2006; 95(8):1122-1123

Neal DE. SIGN: No. 85 - Management of transitional cell carcinoma of the bladder. Clin Oncol (R Coll Radiol) 2006; 18(9):700-701

Rodgers M, Nixon J, Hempel S, Aho T, Kelly J, Neal D, Duffy S, Ritchie G, Kleijnen J, Westwood M. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation. Health Technol Assess 2006; 10(18):III-+

Donovan JL, Hamdy FC, Neal DE. Screening for prostate cancer - The case against. Ann R Coll Surg Engl 2005; 87(2):90-91

Donovan JL, Martin RM, Neal DE, Hamdy FC. Prostate cancer: screening approaches. Hosp Med 2005; 66(11):623-626

Kelly JD, Neal DE. Can a point-of-care proteomic assay increase the accuracy of cystoscopy? Nat Clin Pract Urol 2005; 2(7):320-321

Neal DE. Molecular medicine and its impact on practice. Nat Clin Pract Urol 2005; 2(2):59-59

Neal D. Recommendations for urological cancers issued by NICE. Clin Oncol (R Coll Radiol) 2003; 15(2):57-58

Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet 2003; 361(9366):1359-1367